CARTPT and dementia: It is encouraged that some patients with neurodegenerative diseases, such as dementia with Lewy bodies [10] have shown a reduced level of CART in their cerebrospinal fluid, indicating the clinical importance of this peptide and it may be a biomarker or therapeutic target for such disease.